Natixis Purchases Shares of 215,300 LifeMD, Inc. $LFMD

Natixis acquired a new position in shares of LifeMD, Inc. (NASDAQ:LFMD) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 215,300 shares of the company’s stock, valued at approximately $2,932,000. Natixis owned 0.45% of LifeMD at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Arrowstreet Capital Limited Partnership grew its holdings in LifeMD by 1,767.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock valued at $5,924,000 after purchasing an additional 411,651 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of LifeMD by 581.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares during the last quarter. Jump Financial LLC grew its stake in shares of LifeMD by 205.0% during the 2nd quarter. Jump Financial LLC now owns 515,052 shares of the company’s stock valued at $7,015,000 after buying an additional 346,171 shares during the period. Invesco Ltd. increased its holdings in shares of LifeMD by 1,904.0% during the 2nd quarter. Invesco Ltd. now owns 327,080 shares of the company’s stock worth $4,455,000 after buying an additional 310,759 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in shares of LifeMD during the 1st quarter worth $1,545,000. 35.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Lake Street Capital reduced their target price on LifeMD from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Loop Capital set a $8.00 price objective on LifeMD in a report on Monday, November 24th. Mizuho decreased their target price on LifeMD from $8.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, November 19th. KeyCorp dropped their target price on shares of LifeMD from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Wednesday, November 19th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of LifeMD in a report on Monday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, LifeMD has a consensus rating of “Hold” and a consensus target price of $9.25.

LifeMD Stock Performance

LFMD stock opened at $3.61 on Thursday. The firm has a market cap of $173.79 million, a P/E ratio of -21.24 and a beta of 1.36. LifeMD, Inc. has a 1 year low of $3.42 and a 1 year high of $15.84. The stock has a 50-day simple moving average of $5.20 and a 200-day simple moving average of $8.05.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The company had revenue of $60.17 million during the quarter, compared to analysts’ expectations of $62.07 million. During the same quarter in the previous year, the business earned $0.09 earnings per share. On average, equities research analysts predict that LifeMD, Inc. will post -0.56 EPS for the current year.

LifeMD Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.